anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Movement disorders such as cervical dystonia, blepharospasm, and hemifacial spasm negatively impact the quality of life of people living with these conditions. Botulinum toxin (BoNT) injections are commonly used to treat these disorders. We sought to describe patient characteristics, BoNT utilization, and potential adverse events (AEs) among patients with cervical dystonia, blepharospasm, and hemifacial spasm using Optum's de-identified Clinformatics® Data Mart Database. Patients were required to have a diagnosis of the specific condition plus evidence of treatment with BoNT between 8/1/2010 and 5/31/2022. Cervical dystonia patients were commonly females (76%) and aged 45 and older (78%); both blepharospasm and hemifacial spasm patients were commonly females (both 69%) and aged 65 and older (61% and 56%, respectively). Anticholinergics were commonly used (65-82% across cohorts), as were peripheral muscle relaxants for cervical dystonia patients specifically (31%). The median number of injections per year was 2 with the median weeks between injections being between 13 and 15. Of the AEs evaluated, dyspnea was identified frequently across all the cohorts (14-20%). The findings were similar for different BoNT formulations. More research is needed to thoroughly describe BoNT utilization, such as the doses injected, and to optimize treatment for patients with these conditions.
The invention relates to medicine for treatment of burns. The following five types of natural Chinese medicine are used: wine-soaked ox gall, red sand lotus, pubescent holly root, fried aloe and camellia oil. The best season of excavation is selected according to pharmacological effects of medicine to absorb nimbus and maintain the best pharmacodynamics. An original process for processing of traditional Chinese medicine is adopted, such as selection, washing, drying, crushing, peeling, milling, cooking, grinding, cutting, gentle frying with mild fire, heating and boiling. Active ingredients of the medicine can be guaranteed to the largest extent. Pharmacology of traditional Chinese medicine accumulated in thousands of years and folk remedies are adopted in the formula, effects of traditional Chinese medicine on blood and qi circulation are utilized reasonably, effects of heat removal, detoxification, bacterial prevention and sterilization can be achieved, the skin can be protected effectively from being infected, and no scar can be left. The current international advanced level has been achieved, and the overall efficacy is significantly higher than the efficacy of surgeries with Western medicine. Due to the treatment mode with water pumping and injection, various defects caused by Western medicine to patients and large scars left after surgeries can be avoided. The medicine is bottled and can be conveniently stored, carried and used.
The invention discloses a fusion model-based infant cerebral palsy auxiliary diagnosis system, wherein a data preprocessing module receives infant action sequence data and performs data processing through an interpolation method. And the coordinate preprocessing module carries out median filtering and smoothing processing on the data after interpolation processing, and simultaneously carries out posture normalization. The feature extraction module calculates the features of different joints and trunk motions from the preprocessed coordinate sequence, and then performs stitching to obtain the motion features. The fusion model module inputs the motion characteristics into a plurality of machine learning models to perform bipartite discrimination, combines the discrimination results with the motion characteristics, and inputs the meta model to obtain classification results. The result visualization module visualizes the classification result and provides auxiliary reference for diagnosis. The invention obviously reduces the workload of doctors in screening infant cerebral palsy and provides powerful support for the healthy growth and development of infants.
The diet quality of US adults is poor and cross-sectional analyses suggest self-perception of healthful dietary intake may be overestimated. This analysis assessed the concordance between calculated and perceived diet quality and changes in diet quality among adults seeking weight loss and enrolled in a 12-month randomized behavioral trial. Healthy Eating Index-2015 diet quality (HEI) was calculated from self-administered 24-hour recalls. Perceived diet quality (PDQ) was measured on a 100-point scale. Higher scores indicate better diet quality. Concordance was assessed using the concordance correlation coefficient and Bland-Altman plots. The one hundred and five participants with complete dietary data were mostly female and white. There was good agreement between HEI and PDQ scores at 12 months for less than a third of participants. Most of the disagreement arose from PDQ scores being higher than HEI scores. Even fewer participants had good agreement between HEI changes and PDQ changes. Participants perceived greater improvement in diet quality than indicated by HEI score changes. Concordance was low at 12 months and for change in diet quality. Despite the diet quality of adults seeking weight loss being suboptimal and not improving, many perceived their diet quality and diet quality improvements as better than calculated. Future studies might explore the effect of misperceptions on weight loss outcomes.
This is a Phase 2b double-blind, randomized, placebo-controlled parallel-group study evaluating the safety and efficacy of arimoclomol (400 mg t.i.d.) compared to placebo. A safety lead-in phase will be employed to ensure the safety of all study volunteers.

Tier I (Safety Lead-in): During the enrollment period for the safety lead-in phase, 24 volunteers meeting inclusion/exclusion criteria will be randomized at 4 investigative sites. These volunteers will have weekly visits during the first 4 weeks after starting treatment. Pharmacokinetics (PK) will be performed at various timepoints throughout these 4 weeks. After the initial 4 weeks of treatment, visits will continue at 4-week intervals up to Week 36, subsequently visits will occur every 8 weeks up to Week 68. A final visit will occur at Week 72. There will be a 28-day post study medication Follow-Up Telephone Call to assess medical status and adverse events.

Tier II: After the Tier I volunteers finish 4 weeks of treatment, their data will be reviewed by the IDMC and, if no serious safety issues are identified, the recommendation will be made to start the second enrollment period (Tier II). During Tier II enrollment, volunteers recruited from approximately 30 to 40 centers in the US and Canada will be randomized. After screening and randomization, volunteers will be followed every 4 weeks for 9 months. Subsequently visits will occur every 8 weeks up to Week 68, with interim Follow-Up Telephone Calls at Weeks 16, 24, and 32 and a final visit at Week 72. A Week 76 Follow-Up Telephone Call to assess medical status and adverse events will occur at 28 days post last dose of study medication.
NEW MATERIAL:A polymerizable phosphoric monoester shown by the formulaI(R is H or CH3; n is 2, 3, or 4). EXAMPLE:2-{p-[2-(Methacryloyloxy)ethoxy]phenoxy}ethyl dihydrogen phosphate. USE:A strong adhesive for dental use and for metal. Preferably usable as a composition consisting of it, a copolymerizable vinyl compound and a curing agent. PROCESS:A diol shown by the formula II is reacted with (meth)acrylic acid to give a mixture of a monoester and diester of the diol, which is reacted with equimolar or more phosphorus oxychloride based on the monoester. The P-Cl bond of the prepared compound is hydrolyzed, OH of the monoester is phosphorylated, so that a compound shown by the formulaIis isolated and prepared from the mixture of the monoester and diester.
The study consists of a screening/run-in period where, after meeting study criteria, patients enter a run-in period lasting 7 to 14 ±2 days, during which diary and medication compliance, as well as inhaler technique, will be assessed. The run-in period will commence the day following the completion of all screening procedures and will continue through to and include the day prior to the first treatment visit (TV1) such that a minimum of 7 full days of diary data will be collected prior to TV1. The purpose of the run-in period is to assess compliance with a BID dosing regimen and with the completion of the diary entries over a minimum period of 7 days. Patients who demonstrate adequate inhaler technique and who are at least 90% compliant with dosing and completion of the diary on the last 7 consecutive days of run-in will qualify for enrollment into the open-label study. The study treatment period will comprise 6 treatment visits (TV1-TV6) for all enrolled patients except those in the 5-week treatment cohort who will have only 5 treatment visits (TV1-TV5). Patients may continue taking their current asthma or COPD medications throughout the Treatment Period. The patient will return to the clinic on Days 8 (±1), 15 (±1), 22 (±1), and 36 (±1), and then on Day 50 (-2) after approximately all 200 doses have been delivered, or until early withdrawal. The patient will be deemed to have completed the study if at least 90% of the recommended doses contained in Albuterol Spiromax with dose-counter were used. A representative sample (approximately 15%) of patients will participate in the trial for approximately 5 weeks with Day 36 (±1) being the final study visit.
The invention belongs to an external thermal therapy bag made of traditional Chinese medicine for external application for treating aches and pains in human necks, shoulders, waists and legs. The conventional treatment includes medication, physical treatment, acupuncture, massage and the like. The treatment with western medicaments is usually implemented by using analgesic antipyretics which can relieve aches and pains temporarily, but are not suitable for long-term treatment. The aim of the invention is to treat aches and pains in necks, shoulders, waists and legs by combining a traditional Chinese medicinal formula and mineral elements. The 14 kinds of raw material medicaments of the external thermal therapy bag include myrrh, szechuan lovage rhizome, pepper, incised notopterygium rhizome, garden balsam stem, unprocessed radix aconite and the like; the raw material medicaments are crushed, screened and uniformly mixed with sodium chloride natural mineral element particles; and the mixed is filled into a cloth bag made of pure cotton, and cloth bag is sealed to be used as external thermal therapy bag for heating. The external thermal therapy bag has the advantages that: the clinic treatment of 208 people with cervical spondylosis show that the rate of effectiveness is 47.60 percent and that the total rate of effectiveness is up to 97.67 percent; and the aches and pains in necks, shoulders, waists and legs, which are caused by cervical spondylosis, scapulohumeral periarthritis, lumbar muscle strain, protrasion of the lumbar intervertebral disci, soft tissue injury and the like can be cured effectively.
Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
BACKGROUND: An increase in patients with multidrug-resistant organisms and associated outbreaks during the COVID-19 pandemic have been reported in various settings, including low-endemic settings. Here, we report three distinct carbapenem-resistant Acinetobacter baumannii (CRAB) outbreaks in five intensive care units of a university hospital in Berlin, Germany during the COVID-19 pandemic.
METHODS: A case-control study was conducted with the objective of identifying risk factors for CRAB acquisition in outbreak situations. Data utilized for the case-control study came from the investigation of three separate CRAB outbreaks during the COVID-19 pandemic (August 2020- March 2021). Cases were defined as outbreak patients with hospital-acquired CRAB. Controls did not have any CRAB positive microbiological findings and were hospitalized at the same ward and for a similar duration as the respective case. Control patients were matched retrospectively in a 2:1 ratio. Parameters routinely collected in the context of outbreak management and data obtained retrospectively specifically for the case-control study were included in the analysis. To analyze risk factors for CRAB acquisition, univariable and multivariable analyses to calculate odds ratios (OR) and 95% confidence intervals (CI) were performed using a conditional logistic regression model.
RESULTS: The outbreaks contained 26 cases with hospital-acquired CRAB in five different intensive care units. Two exposures were identified to be independent risk factors for nosocomial CRAB acquisition by the multivariable regression analysis: Sharing a patient room with a CRAB patient before availability of the microbiological result was associated with a more than tenfold increase in the risk of nosocomial CRAB acquisition (OR: 10.7, CI: 2.3-50.9), while undergoing bronchoscopy increased the risk more than six times (OR: 6.9, CI: 1.3-38.1).
CONCLUSIONS: The risk factors identified, sharing a patient room with a CRAB patient and undergoing bronchoscopy, could point to an underperformance of basic infection control measure, particularly hand hygiene compliance and handling of medical devices. Both findings reinforce the need for continued promotion of infection control measures. Given that the outbreaks occurred in the first year of the COVID-19 pandemic, our study serves as a reminder that a heightened focus on airborne precautions should not lead to a neglect of other transmission-based precautions.
An enhanced delivery vehicle for a treating agent includes a base delivery vehicle, which is adapted for carrying a treating agent for uptake thereof by a target cell, and an enhancing component. The enhancing component may be at least one energy rich substance, at least one agent which increases production of at least one energy rich substance in the target cell, or a combination thereof. The enhancing component enhances the uptake of the base delivery vehicle by the target cell. Non-limiting examples of the base delivery vehicle include exosomes, microvesicles, apoptotic bodies, oncosomes, extracellular vesicles, microparticles, liposomes, and nanoparticles. In one embodiment, the enhancing component is an exosome engineered to be substantially devoid of endogenous nucleic acids. In one embodiment, the enhancing component is at least one energy rich substance including, but not limited to, ATP, NADH, NADPH, FADH2, acetyl CoA, glucose, pyruvate, GTP, CTP, and UTP.
BACKGROUND: There is a paucity of evidence regarding the definition of the quality of primary health care (PHC) in China. This study aims to evaluate the PHC quality for chronic diseases in rural areas based on a modified conceptual framework tailored to the context of rural China.
METHODS: This comprehensive study, involving a patient survey, a provider survey and chart abstraction, and second-hand registered data, was set in three low-resource counties in rural China from 2021 to 2022. Rural patients with hypertension or type 2 diabetes, and health care workers providing care on hypertension or diabetes were involved. The modified PHC quality framework encompasses three core domains: a competent PHC system (comprehensiveness, accessibility, continuity, and coordination), effective clinical care (assessment, diagnosis, treatment, disease management, and provider competence), and positive user experience (information sharing, shared decision-making, respect for patient's preferences, and family-centeredness). Standardized PHC quality score was generated by arithmetic means or Rasch models of Item Response Theory.
RESULTS: This study included 1355 patients, 333 health care providers and 2203 medical records. Ranging from 0 (the worst) to 1 (the best), the average quality score for the PHC system was 0.718, with 0.887 for comprehensiveness, 0.781 for accessibility, 0.489 for continuity, and 0.714 for coordination. For clinical care, average quality was 0.773 for disease assessment, 0.768 for diagnosis, 0.677 for treatment, 0.777 for disease management, and 0.314 for provider competence. The average quality for user experience was 0.727, with 0.933 for information sharing, 0.657 for shared decision-making, 0.936 for respect for patients' preferences, and 0.382 for family-centeredness. The differences in quality among population subgroups, although statistically significant, were small.
CONCLUSION: The PHC quality in rural China has shown strengths and limitations. We identified large gaps in continuity of care, treatment, provider competence, family-centeredness, and shared decision-making. Policymakers should invest more effort in addressing these gaps to improve PHC quality.
The present invention discloses a Jinshazaowang milk tablet (milk powder or milk biscuit) for treating diarrhea and a preparation method thereof. The Jinshazaowang milk tablet for treating diarrhea is mainly prepared from oleaster (small fruit), gallnut, manna, red date, white granulated sugar, cream, egg white, antioxidant, a synergistic agent, calcium dipropionate (or sodium propionate), ascorbic acid, etc. The Jinshazaowang milk tablet for treating diarrhea has the functions of strengthening the spleen and stomach, aiding digestion, relieving diarrhea with astringents, securing essential qi, strengthening and invigorating the body, relieving inflammation, reinforcing the spleen, regulating the stomach, benefiting qi for promoting production of fluid, removing toxicity, etc. The Jinshazaowang milk tablet for treating diarrhea is used for treating diarrhea, indigestion, insufficiency of the spleen, cold diarrhea and other diseases by dietotherapy. The oleaster (small fruit), the gallnut, the manna, the red date and the white granulated sugar are prepared, detoxified in a hydration mode according to the proportion requirement of the formula, pulverized, dried, irradiated by far infrared rays to be sterilized, mixed and stirred; the cream, the egg white, the antioxidant, the synergistic agent, the ascorbic acid and the calcium dipropionate or sodium propionate used as an antitoxic agent are added to the mixture to be thoroughly stirred and mixed, and then are sent to a forming machine so as to be processed by procedure operation; the formed tablet is irradiated by ultraviolet rays to be sterilized, vacuumized and quantitatively packaged. The Jinshazaowang milk tablet for treating diarrhea has the characteristics of safe eating, low cost, abundant raw material, no toxic or side effect, etc.; since the Jinshazaowang milk tablet for treating diarrhea is refined scientifically and disinfected at high temperature so as to be quickly cured; the Jinshazaowang milk tablet.
Patients receive ibrutinib PO QD on days 1-28. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1, and on day 1 of cycles 2-6. Beginning cycle 3, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity. All patients will then receive a 15th cycle of ibrutinib. Beginning cycle 16, patients who do not achieve a BM MRD negative CR, receive ibrutinib PO QD every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a BM MRD negative CR undergo observation every 3 cycles for 6 years, then every 6 cycles thereafter.
The nucleosides availability is a crucial factor governing the proliferation of any living entities (viruses, bacteria, parasites or eukaryotic cells). The enzyme involved in the fourth step of the de novo pyrimidine nucleotides biosynthetic pathway, where L-dihydroorotate (DHO) is converted to orotate (ORO), is named dihydroorotate dehydrogenase (DHODH). This enzyme has been recognized as a promising target for the treatment of autoimmune diseases, cancers and infections. However, there is a still a need for identifying new synergic combinations with DHODH inhibitors. The inventors show synergistic effect of DHODH inhibitors and IDH inhibitors on the proliferation of cancer cell lines. The present invention thus relates to methods of therapy comprising administering a therapeutically effective combination comprising a DHODH inhibitor and an IDH inhibitor.
The pathological role of interferon signaling is emerging in neuroinflammatory disorders, yet, the specific role of Interferon Regulatory Factor 3 (IRF3) in neuroinflammation remains poorly understood. Here, we show that global IRF3 deficiency delays TLR4-mediated signaling in microglia and attenuates the hallmark features of LPS-induced inflammation such as cytokine release, microglial reactivity, astrocyte activation, myeloid cell infiltration, and inflammasome activation. Moreover, expression of a constitutively active IRF3 (S388D/S390D: IRF3-2D) in microglia induces a transcriptional program reminiscent of the Activated Response Microglia and the expression of genes associated with Alzheimer's disease, notably apolipoprotein-e. Using bulk-RNAseq of IRF3-2D brain myeloid cells, we identified Z-DNA binding protein-1 (ZBP1) as a target of IRF3 that is relevant across various neuroinflammatory disorders. Lastly, we show IRF3 phosphorylation and IRF3-dependent ZBP1 induction in response to Aβ in primary microglia cultures. Together, our results identify IRF3 as an important regulator of LPS and Aβ -mediated neuroinflammatory responses and highlight IRF3 as a central regulator of disease-specific gene activation in different neuroinflammatory diseases.
The emergence of treatment de-escalation as a feasible option for patients with newly diagnosed human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma has generated considerable excitement among both providers and patients alike. Since HPV-positive oropharyngeal carcinoma has been shown to be a unique entity with distinct clinical and molecular characteristics, the rationale for customizing treatment for patients with this disease is compelling. Indeed, evidence has accumulated demonstrating that patients with HPV-positive oropharyngeal cancer have a significantly improved prognosis as a result of their exquisite radiosensitivity compared to their HPV-negative counterparts and thus might possibly be targeted with de-escalated approaches. The fundamental goal of de-escalation is to maintain the high cure and survival rates associated with traditional approaches while reducing the intensity of treatment and thus the incidence of both short- and long-term toxicity. Given the rapidly increasing incidence of this disease, particularly among younger patients who are generally healthy, the focus on quality of life seems germane. Although the exact reason for the improved sensitivity of HPV-positive oropharyngeal carcinoma to treatment is uncertain, prospective studies have now been published demonstrating that de-escalated radiation can successfully maintain the high rates of cure and preserve quality of life for appropriately selected patients with this disease. However, these studies have been fairly heterogeneous in design, and it remains questionable how to apply their findings to real-world practice. The potential of integrating translational approaches into clinical paradigms is also just starting to become recognized. Consequently, multiple uncertainties continue to exist with respect to de-escalation for HPV-positive oropharyngeal cancer, and these questions comprise the crux of this review.